Close
FINDING CURES TOGETHER<sup>SM</sup>

The Hippo Pathway: Signaling, Cancer, and Beyond

Wednesday, May 8   

Thursday, May 9

Friday, May 10

Saturday, May 11

Wednesday, May 8 

Registration
4-8 p.m.

Welcome and Keynote Lecture
7-8 p.m.

Targeting developmental pathways in cancer
Frederic J. de Sauvage, Genentech, Inc., South San Francisco, California

Opening Reception
8-9:30 p.m.


Thursday, May 9 

Continental Breakfast
7:30-8:30 a.m.

Plenary Session 1: Mechanisms of Hippo Pathway Regulation in Cancer
Session Chair: Duojia D.J. Pan, Howard Hughes Medical Institute, Dallas, Texas
8:30-10:30 a.m.

Hippo signaling in normal and cancer growth
Duojia D.J. Pan

The Hippo pathway in melanoma
Kieran F. Harvey, Peter MacCallum Cancer Centre, East Melbourne, Australia

Regulation of the Hippo pathway in cancer
Kun-Liang Guan, UCSD Moores Cancer Center, La Jolla, California

Regulation of TEAD by p38 MAPK-induced cytoplasmic translocation*
Hyun Woo Park, Yonsei University, Seoul, South Korea

Concerted localization resets precede YAP-dependent transcription*
Matt Franklin, Stanford University, Stanford, California


Break
10:30-11 a.m.


Plenary Session 2: Hippo Pathway in Rare/Pediatric Cancers
Session Chair: Brian P. Rubin, The Cleveland Clinic, Cleveland, Ohio
11 a.m.-12:30 p.m.

Hippo pathway dysregulation in epithelioid hemangioendothelioma
Brian P. Rubin

Dysregulated Hippo signaling in childhood rhabdomyosarcoma
Corinne Mary Linardic, Duke University School of Medicine, Durham, North Carolina

YAP/TAZ requirement in mesenchyme-originated intestinal hamartomatous polyposis*
Junhao Mao, University of Massachusetts Medical School, Worcester, Massachusetts

Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion positive NSCLC *
Franziska Haderk, University of California, San Francisco, California


Poster Session A / Lunch
12:30-2:30 p.m.


Plenary Session 3: Hippo Signaling in Stem Cells and Regeneration and Links with Other Key Signaling Pathways
Session Chair: Georg Halder, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
2:30-4:15 p.m.

Hippo signaling in liver regeneration and liver tumors
Georg Halder

Regulation of YAP by tyrosine phosphorylation of core Hippo pathway components: Lessons learned from the GNAQ oncogene and FAK
J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, California

Inhibition of the Hippo pathway by AMPK-family kinases
Liliana Attisano, University of Toronto, Canada

The cell type-specific roles of YAP/TAZ in pancreatic cancer development*
David Eisenbarth, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea


Break
4:15-5 p.m.


Plenary Session 4: Transcriptional Regulation in Cancer and Beyond
Session Chair: Yingzi Yang, Harvard School of Dental Medicine, Boston, Massachusetts
5-6:30 p.m.

Hippo signaling is intrinsically regulated during cell cycle progression 
Yingzi Yang

Targeting autopalmitoylation of TEAD transcription factors
Xu Wu, Massachusetts General Hospital, Boston, Massachusetts

Genome-wide screening identifies novel YAP modulators*
Dana Elster, Leibniz Institute on Aging, Fritz Lipmann Institute e.V., Jena, Thüringen, Germany

Mechanistic insights for TEAD/YAP activation*
Jeffrey Holden, Genentech, South San Francisco, California


Evening Off / Dinner on Own
6:30 p.m.-

Top of page


Friday, May 10 

Continental Breakfast
7:30-8:30 a.m.


Plenary Session 5: Regulatory Networks, Cancer Pathway Crosstalk, and Integration of Model Systems
Session Chair: Nicolas Tapon, The Francis Crick Institute, London, United Kingdom
8:30-10:30 a.m.

Regulation of the Hippo pathway in cancer
Fernando Camargo, Boston Children's Hospital, Boston, Massachusetts

The roles of YAP/TAZ in tumor maintenance
Chunling Yi, Georgetown University, Washington, DC

Growth control and Hippo signaling in the Drosophila abdomen 
Nicolas Tapon

Regulation of SAV1-STRIPAK antagonism by YSK1-dependent phosphorylation
Xuelian Luo, UT Southwestern Medical Center, Dallas, Texas


Break
10:30-11 a.m.


Plenary Session 6: Drugging the Hippo Pathway
Session Chair: Wanjin Hong, Institute of Molecular and Cell Biology, Proteos, Singapore
11 a.m.-12:30 p.m.

Hippo pathway deregulation in cancers
Anwesha Dey, Genentech, Inc., South San Francisco, California

Targeting the Hippo pathway for candidate cancer therapy
Wanjin Hong

Targeting the Hippo-YAP pathway with small molecule compounds*
Tracy Tang, Vivace Therapeutics, San Mateo, California

Systematic pan-cancer analyses of Hippo pathway deregulation in cancer*
Matthew Chang, Genentech, South San Francisco, California


Free Time / Lunch on Own
12:30-2:30 p.m.


Plenary Session 7: Therapy and Resistance Factors in Cancers
Session Chair: Bin Zhao, Zhejiang University, Hangzhou, China
2:30-4:30 p.m.

Integrin-mediated mechano-transduction controls HER2 oncogenic signaling and activation of YAP in breast cancer
Filippo G. Giancotti, UT MD Anderson Cancer Center, Houston, Texas

LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state 
Yael Aylon, Weizmann Institute of Science, Rechovot, Israel

The Hippo pathway in cancer 
Bin Zhao

The Hippo pathway integrates PI3K-Akt signals with mechanical cues to control tissue growth
Barry Thompson, Francis Crick Institute, London, England, United Kingdom


Poster Session B / Reception
4:30-6:30 p.m.


Free Time / Dinner on Own
6:30 p.m.-

Top of page


Saturday, May 11 

Continental Breakfast
7:30-8:30 a.m.


Plenary Session 8: Hippo Pathway, Inflammation, Microenvironment, and Cancer Immunity
Session Chair: Ira Tabas, Columbia University Health Sciences, New York, New York
8:30-10:30 a.m.

The role of hepatocyte TAZ in NASH and NASH-HCC
Ira Tabas

YAP signaling in cancer and inflammation
Deepavali Chakravarti, University of Texas MD Anderson Cancer Center, Houston, Texas

Paracrine orchestration of intestinal tumorigenesis at the mesenchymal-epithelial interface*
Manolis Roulis, Yale School of Medicine, New Haven, Connecticut

Hippo regulates intestinal regeneration by inducing revival stem cells*
Jeff Wrana, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada


Break
10-10:30 a.m.


Plenary Session 9: Broader Roles in Cancer Signaling
Session Chair: Helen McNeill, Washington University, St. Louis, Missouri
10:30 a.m.-12 p.m.

Adult deletion of Lats1/2 leads to sarcomatoid renal cell carcinoma 
Helen McNeill

Oncogenic LncRNA promotes escape from intrinsic Hippo tumor suppression 
Liuqing Yang, University of Texas MD Anderson Cancer Center, Houston, Texas

Regulation of Hippo and TAZ signaling in breast cancer 
Kunxin Luo, University of California, Berkeley, California


Closing Remarks
12-12:15 p.m.

Fernando Camargo, Boston Children's Hospital, Boston, Massachusetts
Anwesha Dey, Genentech, Inc., South San Francisco, California
Kun-Liang Guan, UCSD Moores Cancer Center, La Jolla, California

*Short talk from proffered abstract


Top of page